Mesenchymal stem cells (MSCs) are multipotent progenitor cells that can differentiate into several cell types. Bone marrow (BM)-MSCs mainly differentiate into osteoblasts or adipocytes. MSC interactions with their microenvironment directly affect their self-renewal/differentiation program. Here, we show for the first time that Fas ligand (FasL), a well-explored proapoptotic cytokine, can promote proliferation of BM-derived MSCs in vitro and inhibits their differentiation into adipocytes. BM-MSCs treated with a low FasL dose (0.5 ng/ml) proliferated more rapidly than untreated cells without undergoing spontaneous differentiation or apoptosis, whereas higher doses (25 ng/ml) induced significant though not massive BM-MSC death, with surviving cells maintaining a stem cell phenotype. At the molecular level, 0.5 ng/ml FasL induced ERK1/2 phosphorylation and survivin upregulation, whereas 25 ng/ml FasL induced caspase activation. Importantly, 25 ng/ml FasL reversibly prevented BM-MSC differentiation into adipocytes by modulating peroxisome proliferator-activated receptor gamma (PPARc) and FABP4/aP2 expression induced by adipogenic medium. All such effects were inhibited by anti-Fas neutralizing antibody. The in vitro data regarding adipogenesis were confirmed using Fas lpr mutant mice, where higher PPARc and FABP4/aP2 mRNA and protein levels were documented in whole tibia. These data show for the first time that the FasL/Fas system can have a role in BM-MSC biology via regulation of both proliferation and adipogenesis, and may have clinical relevance because circulating Fas/FasL levels decline with age and several age-related conditions, including osteoporosis, are characterized by adipocyte accumulation in BM.
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However, BM-MSCs are also found at low frequency in most adult connective tissues. 2 The interactions of BM-MSCs with their microenvironment directly affect their stem cell self-renewal or differentiation program, which includes osteogenesis and adipogenesis. In addition to hematopoietic progenitors and their progeny, several cell types (e.g. fibroblasts, endothelial cells, osteoblasts, osteoclasts, adipocytes, and immune cells) supply factors to BM-MSCs; in turn, BM-MSCs are essential for HSC differentiation, mobilization, and exit from the marrow compartment. 3 A number of factors have important roles in BM-MSC proliferation and stemness maintenance, including basic fibroblast growth factor (bFGF), 4 heparin-binding epidermal growth factor-like growth factor (HB-EGF), 5 and interleukin 6 (IL-6), 6 whereas factors such as bone morphogenic proteins, insulin, and insulin-like growth factor IGF1 7, 8 induce BM-MSC differentiation into osteoblasts and adipocytes.
Commitment of BM-MSCs to the osteoblast or adipocyte fate occurs through a highly regulated mechanism, where lineage-specific transcription factors are ultimately activated. The master transcriptional regulator of adipogenesis is peroxisome proliferator-activated receptor gamma (PPARg). Its transcripts generally increase more than 10-fold within a few days of adipogenic stimulation. Furthermore, PPARg has a crucial role in the function of fat cell-specific genes during late differentiation. 9 A variety of downstream genes are then induced, which contribute to acquisition of the mature phenotype, including adiponectin and the adipocyte binding protein FABP4/aP2. 10, 11 BM adipogenesis is a physiological process. Marrow fat has a variety of functions, including maintenance of the bone microenvironment and of bone energy. 12 However, excessive or poor marrow fat is a feature of several pathological conditions, including multiple myeloma, anorexia nervosa, osteoarthritis, osteoporosis related to advanced age, and HIV-associated lipodystrophy. 3, 13, 14 During aging, B-MSCs lose some of their differentiation potential. It has been proposed that MSCs are by default programmed to differentiate into adipocytes, but that the optimal osteoblastogenesis conditions found in young bone are impaired by the aging process, resulting in excessive adipogenesis. 15 A factor for which a role in bone differentiation and homeostasis is emerging is Fas ligand (FasL). Although FasL was initially described as a T-cell-associated protein capable of inducing apoptosis by binding to its receptor Fas, 16 a pleiotropic role in other cell populations has also been described over the last few years. The Fas/FasL system has a number of actions that include induction of proapoptotic signals in normal cells, immune system homeostasis regulation, and enhancement of the resistance of most cancer cells to its own proapoptotic signals. 17 Fas engagement in resting T lymphocytes transduces inhibitory or costimulatory signals in a FasL dose-dependent manner, 18 and in hematopoietic progenitors FasL receptor transduces dual apoptotic and trophic signals via caspase-dependent and -independent molecular mechanisms, respectively. 19 There are two physiologically active forms of FasL, membrane-bound (mFasL) and soluble (sFasL): mFasL is essential for Fas-induced killing of target cells and activation-induced cell death, whereas sFasL induces non-apoptotic signals, possibly including stimulation of cell proliferation, survival, or inflammation within an elevated cytokine milieu. 20 Therefore, mFasL is essential for cytotoxic activity and protects against autoimmunity and cancer, whereas excess sFasL appears to promote autoimmunity, tumorigenesis and cancer progression through non-apoptotic actions. 20, 21 Several conditions have been associated to and could be mediated by increased circulating sFasL levels, including AIDS, 22, 23 acute myocardial infarction, 24 and Graves' hyperthyroidism. 25 Besides its death-promoting activity, FasL has been implicated in reverse signaling and might thus also have a role in T-cell development and selection and in TCR signaling modulation, functioning as a typical costimulator. 26 Finally, the FasL intracellular domain can be released into cytosol, enter the nucleus and directly modulate transcriptional activity. 27 Fas and FasL are expressed in freshly isolated BM-MSCs, both human and mouse. 28, 29 However, cell death induction does not seem to be the Fas/FasL system's main role in bone homeostasis. Fetal BM-MSCs have been shown to have functional extrinsic apoptotic pathways, 30, 31 whereas adult BM-MSCs are resistant to Fas-mediated apoptosis. 29 Furthermore, FasL has a limited role in osteoblast and osteoclast apoptosis, but inhibits osteoblast differentiation in mice. 28 During osteoblastogenesis FasL expression rapidly decreases and remains low until the end of the differentiation process, whereas Fas levels rise. 28, 32 Even more importantly, absence of Fas and FasL stimulates osteoblast differentiation, as both Fas À / À and gld mice have greater osteoblastogenic potential than control mice. 28 These findings suggest that the Fas/FasL system has a role in controlling the BM-MSC differentiation program.
We investigated the effect of FasL on BM-MSC apoptosis, proliferation, and differentiation into adipocytes to clarify the role of the Fas/FasL system in BM-MSC biology. Here we show for the first time that FasL exerts a pleiotropic action on BM-MSCs depending on its concentration: low doses induce proliferation, whereas higher doses have a slight but significant apoptotic effect and, more importantly, inhibit adipogenesis; all such effects are exerted without affecting BM-MSC stemness, irrespective of dosage.
Our findings show a FasL-dependent regulation of BM-MSC biology and adipogenesis, and suggest a role for FasL in conditions involving altered BM adipogenesis, such as osteoporosis in the elderly.
Results
FasL has a dose-dependent dual effect on BM-MSCs. The effect of different doses of human recombinant FasL (from 0.1 to 5 ng/ml) on proliferation of batch no. 1 BM-MSCs was examined on days 2, 4, and 6 of culture ( Figure 1a ). Cell counts indicated that all doses except the highest enhanced cell proliferation, 0.5 ng/ml having the strongest effect (30% increase versus control on day 6). The proliferative effect was not donor-related, as 0.5 ng/ml FasL also increased cell number in batches no. 2 and no. 3 (Supplementary data, Figure 1 ). The effect of this dose was validated by BrdU assay data on day 6 and was neutralized by anti-Fas antibody (Figure 1b) . Cell number comparisons on day 6 showed nonsignificant differences among cultures treated with 0.5 ng/ml FasL and those treated with trophic factors FGF (5 ng/ml) and EGF (50 ng/ml) ( Figure 1c ). To establish whether the proliferative effect of 0.5 ng/ml was transient or persistent, cell numbers were also assayed on day 14; the effect was found to persist at least 14 days into treatment (Figure 1d ).
The effect of higher FasL doses (25 ng/ml) on BM-MSCs (batch no. 1) was also examined on days 1, 2, 4, and 6. FasL reduced cell number (data not shown) and had a significant proapoptotic effect on day 1 (22% of apoptotic cells) that subsequently decreased ( Figure 2a ). As 5 ng/ml FasL reduced BM-MSC proliferation (Figure 1a) , the proapoptotic effect of doseso25 ng/ml FasL (from 0.5 to 2.5 ng/ml) was also examined and compared with the effect of 25 ng/ml FasL. As expected, low doses did not exert a significant proapoptotic effect, whereas 5 ng/ml FasL had a weak proapoptotic effect (7% of apoptotic cells). To compare these data with those obtained by other groups, 29 Fas triggering was also induced with a low (50 ng/ml) or a high dose (1000 ng/ml) of the agonistic anti-Fas antibody (Figure 2b) .
At the molecular level, Fas-induced proapoptotic signaling was assayed on day 1 of culture by examining processing of pro-caspase 8 and 3 that indicates their activation. Figure 2c shows that 0.5 ng/ml FasL had a weak effect, whereas 25 ng/ml FasL induced a decline in pro-caspase 8 and 3 that was inhibited by the pan caspase inhibitor zVAD. However, as fragments of active caspase 3 were not detectable in any experiment on day 1 of treatment ( Supplementary Figure 2b) , its cleavage was assayed (and found) at shorter times (4, 8 , and 12 h) (Figure 2d) . Therefore, the biological effect of FasL on BM-MSC growth and apoptosis is dose-dependent: low doses (0.5 ng/ml) promote cell proliferation and do not induce apoptosis, whereas high doses (25 ng/ml) induce apoptosis of a limited proportion of cells. , and CD90 33 were all expressed in cells treated with 0.5 and in those treated with 25 ng/ml FasL; their levels were comparable to those of untreated cells at both time points (a and b, upper panels) except for CD73, which on day 6 was slightly increased in cells treated with 25 ng/ml FasL. Quantitative real-time PCR (qRT-PCR) analysis of transcription factors Rex-1, Nanog, and Oct-4 and of CD44 mRNA documented the expression of these four molecules in untreated cells both on day 1 and on day 6 (data not shown). Interestingly, their mRNA levels, reported as fold increase versus untreated cells (control), were unchanged at both time points with 0.5 ng/ml (a and b, lower panel), but were slightly increased by 25 ng/ml FasL on day 1 (a, lower panel). These data demonstrate that FasL does not reduce BM-MSC stemness.
FasL induces ERK/1-2 phosphorylation and survivin expression. As in conditions favoring proliferation FasL induces ERK1/2 activation, 21, 34 and BM-MSCs maintain a stem cell phenotype through ERK1/2-dependent mechanisms, 6 we explored ERK1/2 activation in BM-MSCs treated with 0.5 ng/ml FasL. As documented in Figure 4a , FasL induced ERK phosphorylation with two peaks at 5 and 30 min, respectively. Furthermore, as survivin is an important factor for cell death resistance and in particular modulates HSC cycle and proliferation, 35 its expression was determined in proliferating FasL-treated BM-MSCs at different times. Survivin protein expression was lower than in untreated cells on day 2 (Figure 4b ), in line with Rodrigues et al., 31 but it was greater on days 4 and 6. These data lend support to the observation that FasL promotes BM-MSC proliferation ( Figure 1 ).
FasL inhibits BM-MSC differentiation into adipocytes.
It has been reported that FasL inhibits murine osteoblastogenesis 28 , and we found that BM-MSCs survived FasL treatment and retained their stemness characteristics ( Figure 3 ). However, as little information is available on adipogenesis, we assessed the role of FasL in inhibiting BM-MSC differentiation into adipocytes. BM-MSCs were cultured for 14 days in adipogenic medium (AD) alone or supplemented with 0.5 or 25 ng/ml FasL. Cells were then stained with Oil Red O to count adipocytes, and with methylene blue to count total cell number. While 0.5 ng/ml FasL had very little effect on adipogenesis inhibition (data not shown), 25 ng/ml FasL inhibited lipid droplet accumulation (Figure 5a ). The percentage of differentiated cells out of total cell number in each culture condition was compared with the percentage of differentiated cells found in cultures grown in AD alone, considered ¼ 100%. The results showed that in FasL-supplemented AD adipogenesis was inhibited by about 50% (Figure 5b ). For this to happen FasL had to be present throughout the culture time. Importantly, these data are corroborated by the finding that FasL also inhibited AD-induced expression of PPARg, adiponectin, and FABP4/aP2 differentiation genes, as documented by qRT-PCR ( Figure 5c ). All such effects were specific because they were neutralized by ZB4 anti-Fas antibody.
To exclude that adipogenesis impairment in FasL-supplemented cells was due to the proapoptotic action of FasL or to a 
Discussion
This study indicates that FasL exerts a pleiotropic effect on BM-MSCs. Our data document for the first time that FasL can induce in vitro both BM-MSC proliferation and apoptosis depending on its concentration and, more importantly, that it inhibits their differentiation into adipocytes. In particular, treatment with low-dose (0.5 ng/ml) FasL for 6 days increased BM-MSC number by about 30% compared with untreated cultures, in a similar way to EGF and FGF ( Figure 1) ; this effect was still noted in long-term cultures (Figure 1d ). Two important proliferation markers, ERK and survivin, were sought and found in this system. Rapid activation of ERK1/2 phosphorylation was demonstrated within minutes of treatment (Figure 4a ). ERK1/2 activation is induced by EGF combined with bFGF 36 or by IL-6; it is a key pathway through, which IL-6 regulates both proliferation and inhibition of MSC differentiation. 6 Survivin is not only an antiapoptotic factor, but also a critical regulator of cell division, and its expression peaks at mitosis. Its conditional deletion results in mitotic defects, cell death and tissue involution. [37] [38] [39] As shown in Figure 4b survivin expression correlated with FasL-induced proliferation: it was downregulated while FasL-promoted BM-MSC proliferation was still limited (day 2), but upregulated when cells proliferated more rapidly (days 4 and 6) ( Figure 1) . Interestingly, 0.5 ng/ml is a concentration similar to the one found in the sera of young normal subjects 40 (authors' unpublished observations). Therefore, these data suggest a possible physiological role for FasL in promoting BM-MSC proliferation.
In contrast, higher doses (25 ng/ml) had a slight but significant proapoptotic effect involving survival of about 75% of the population (Figure 2 ). These data are consistent and do not contrast with previous findings. Rodrigues et al. 31 showed that FasL kills human BM-MSCs through ROS production, BAD activation, and survivin downregulation.
They used higher FasL doses (100 ng/ml), as their study addressed the death mechanisms of transplanted BM-MSCs in injured tissues, which are characterized by high levels of pro-inflammatory cytokines, including FasL. Kennea et al. 30 found that, 3 days into culture, 25 ng/ml FasL induced apoptosis of about 20% of human fetal MSCs and that 100 ng/ml FasL induced apoptosis in more than half the population. Similarly, Mazar et al. 29 documented both Fas and FasL expression by primary BM-MSCs, concluding that they are resistant to Fas-induced apoptosis. The agonistic anti-Fas antibody used in their experiments, used at concentrations ranging from 10 to 100 ng/ml for 18 h, gave a percentage of apoptotic cells similar to the one shown in our Figure 2 . 29 The additional findings provided by our study are similar expression levels of the stem cell markers in the non-apoptotic population treated with 0.5 ng/ml FasL, and their increment in the survivor population treated with 25 ng/ml, exclusively on day 1 (Figure 3) . One possible explanation for the latter finding is that the proapoptotic dose of 25 ng/ml FasL (Figure 2 ) killed those cells exhibiting a higher Fas expression (committed cells, as Fas expression increases during BM-MSC differentiation 28, 32 ), thus selecting for a population with enhanced stem cell properties (Figure 3 (Figure 5a ) and of PPARg, adiponectin, and FABP4/aP2 mRNA downregulation (Figure 5b ) occurred when AD was continuously supplemented with 25 ng/ml FasL, a concentration that exerted a proapoptotic effect on cells maintained in non-AD for shorter periods (Figure 2a) . Furthermore, adipogenesis inhibition was not induced by the proapoptotic effect of FasL, because pre selection of apoptosis-resistant cells did not reduce adipogenesis inhibition, but rather enhanced it (Figure 6 ). Interestingly, FasL treatment did not abolish the stem cell potential of BM-MSCs, and adipogenesis inhibition was not irreversible, as FasL subtraction restored the adipogenic process (Figure 8) . The demonstration of an in vitro inhibitory effect of Fas/FasL on murine BM-MSC osteoblast differentiation by Kovacić et al. 28 is in line with these data: BM from mice without functional Fas or FasL generates more osteoblast colonies ex vivo than wild-type BM, suggesting a key role for the Fas/ FasL system in osteoblast differentiation. Accordingly, whole tibia of Fas lpr mice expressed higher mRNA and protein levels of PPARg and FABP4/aP2, respectively the master transcription factor of adipogenesis and the principal adipose tissue marker, compared with control mice.
Altogether these data suggest that FasL is involved in maintaining BM-MSC stemness and in controlling differentiation.
An inhibitory effect of FasL on BM-MSC adipogenesis, particularly on lipid droplet accumulation and PPARg, adiponectin and FABP4/aP2 mRNA expression, has never been described before. However, a 1985 study demonstrated that TNFa acts as a polypeptide hormone with pleiotropic effects on cell proliferation and differentiation, and that it is a potent adipogenesis inhibitor. it has been shown that adipogenesis impairs hematopoiesis. 42 Besides having a role in maintaining MSC stemness and in adipogenesis inhibition, FasL could also, conceivably, be involved in regulating hematopoiesis: if this finding were confirmed by further work, FasL would be recognized as a bone homeostasis regulator. Fas and FasL are constitutively expressed in normal adult human BM. Monocytic and, especially, myeloid and CD34 þ cells express high FasL levels; 43 consequently they may all, separately or together, have a role in BM-MSC biology through a closely regulated mechanism. Existing data are insufficient to determine, which FasL form (membrane-bound, soluble, or vesicular) is more relevant to BM-MSC physiology. However, several conditions characterized by altered immune system homeostasis and circulating FasL also show BM adipose tissue changes; for instance sFasL plasma levels in HIV-positive subjects can reach concentrations of 15 ng/ml. 23 Interestingly, a significantly lower fat fraction has been found in BM of HIV-infected compared with non-HIV-infected men. 44 On the other hand circulating FasL can also decrease, for example, during aging, where a progressive decline has been documented in sera 40 and lymphocytes 45 of elderly people. Interestingly, BM adipogenesis occurs spontaneously during aging, resulting in primary osteoporosis. 15, 46 Although a correlation between circulating FasL level and BM adipogenesis has never been investigated, it would be interesting to explore the possible connection between in vivo FasL levels and fat loss or gain in such diseases. This hypothesis is currently being investigated in our lab.
Materials and Methods
Cell culture. Three different batches of human-derived BM-MSCs, No.1 (#110877, 22-year-old male), No.2 (#296577, 45-year-old male), and No.3 (#1F4019, 29-year-old male), were purchased from Lonza (Allendale, NJ, USA) and maintained in a-MEM (Euroclone, 20016, Milano, Italy) supplemented with 10% fetal bovine serum (FBS) (Lonza) and 1% penicillin/streptomycin (f) at 37 1C in a humidified atmosphere containing 5% CO 2 /95% air. Experiments were performed using BM-MSCs up to the fifth passage.
For adipogenic differentiation BM-MSCs were seeded at 5 Â 10 3 cells/cm 2 on six-well plates in AD containing complete a-MEM, 2 mM l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% FBS supplemented with 0.5 mM dexamethasone, 5 mg/ml insulin, 0.2 mM indomethacin, and 0.45 mM isobutylmethylxantine (Sigma-Aldrich, St. Louis, MO, USA). After 24-h FasL and/or neutralizing anti-Fas antibody was added to the cultures. AD medium and treatments were changed twice a week until the end of the experiment. BM-MSCs cultured in complete a-MEM without adipogenic supplements were used as control.
Alternatively, 24 h after seeding 25 ng/ml FasL was added to a À MEM for 2 days; floating apoptotic cells were then removed and the medium replaced with AD supplemented with 25 ng/ml FasL, with or without ZB4 anti-Fas antibody, for 14 days. Reagents. SuperFasLigand and the pan caspase inhibitor zVAD (20 mM) were purchased from Enzo Life Sciences (Farmingdale, NY, USA). Anti-Fas human activating clone CH11 and neutralizing anti-Fas antibody ZB4 were purchased from Millipore (Billerica, MA, USA). EGF was obtained from Upstate (Lake Placid, NY, USA) and FGF from Peprotech (Rocky Hill, NJ, USA).
Proliferation assays. For the growth curve study, BM-MSCs were plated at a density of 5 Â 10 3 cells/cm 2 in six-well plates in complete a-MEM and treated with different doses of FasL (from 0.1 to 5 ng/ml) and/or of neutralizing anti-Fas antibody (500 ng/ml). Positive controls were BM-MSCs treated with FGF (5 ng/ml) or EFG (50 ng/ml). The media were replaced every 2 days until the end of the culture, or twice a week in the case of longer treatments. On days 2, 4, 6, and 14 cells were detached and counted using a hemocytometer. For the BrDU assay, DNA Cell proliferation ELISA BrdU (colorimetric) was purchased from Roche Diagnostics (Mannheim, Germany). Cells were plated in triplicate at 5 Â 10 3 cells/cm 2 in 96-well plates, and treated with FasL alone or with FasL and neutralizing anti-Fas antibody. BrdU labeling solution was added on day 5; plates were read after 24 h incubation according to the manufacturer's instructions (day 6).
Apoptosis evaluation. Cells were plated at 5 Â 10 3 cells/cm 2 on chamber slides (BD, Franklin Lakes, NJ, USA). Attached cells were treated for 1, 2, 4, or 6 days with FasL alone or with human activating CH11 anti-Fas antibody (2 days). The latter was used for a comparative study. Cells were then washed twice with PBS, fixed with 4% paraformaldehyde for 5 min, and stained with Hoechst 33342 (Molecular Probes, Eugene, OR, USA) for 20 min. The percentage of cells with pycnotic nuclei was counted using a fluorescence microscope (Nikon Eclipse 80i, Nikon, Japan) with EX 330-380 and BA 420 filter. At least 10 random fields per treatment were captured and analyzed. Protein extraction and immunoblotting. Cells were washed twice in cold PBS. Total protein was extracted using RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1.0% Triton X-100, 5 mM EDTA, pH 8.0) containing protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). Protein concentration was determined using Bradford Reagent (Sigma-Aldrich, Milano, Italy). Total protein extracts (40 mg) were separated by 10% SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% nonfat dry milk and incubated overnight with anti-survivin (Novus Biologicals, Littleton, CO, USA), mouse anti-caspase 3 (#9668), anti-caspase 8, rabbit polyclonal anti-caspase 3 (#9662) (all from Cell Signaling, Danvers, MA, USA), and b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) primary antibodies. Immunoreactive proteins were visualized using Millipore's Luminata Forte.
For mitogen-activated protein kinase (ERK) phosphorylation assays, cells were starved for 24 h before treatment with 0.5 ng/ml superFasL. Protein was extracted with RIPA buffer containing sodium orthovanadate (1.8 mg/ml). Anti-phospho-ERK and anti-total ERK antibodies were from Cell Signaling and Upstate, respectively. Quantification was performed with Bio-Rad's Quantity-One imaging software, and protein expression calculated as a percentage of the loading control.
Fas lpr mice and mRNA and protein extraction. B6.MRL-Fas lpr /J and C57BL/6J mice (used as control) were purchased from Jackson laboratories (Frederick, MD, USA). They were housed 2-5 per cage in a temperature-and humidity-controlled vivarium with ad libitum water and food, and maintained on a 12 h light/dark cycle. Animal treatment complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and was approved by the Institutional Animal Care and Use Committees.
Ten-week-old mice were euthanized in a CO 2 chamber; both tibias were removed, dissected free of surrounding soft tissue, weighed and immediately frozen. One tibia was used for protein extraction, the other for mRNA extraction. Tibias were homogenized using Precellys 24 homogenizer (Bertin Technologies, Montigny le Bretonneux, France) in MK28-R tubes (2 Â 20 s at 5600 r.p.m.) using (i) RIPA buffer, mini complete protease inhibitors, and 0.01% Triton X-100 for protein preparation, and (ii) Qiagen RNAeasy Plus Universal Mini Kit lysis buffer solution (Qiagen, Düsseldorf, Germany) following the manufacturer's instructions for mRNA extraction. Protein concentration was measured with the BCA method (Pierce, Thermo Scientific, Rockford, IL, USA): equal amounts of protein (5 mg) dissolved in Laemmli loading buffer were loaded in 12 well 4-12% SDS-PAGE precast minigel (Novex, Life Technologies). Proteins were transferred to Invitrolon PVDF membranes (Life Technologies) and hybridized with PPARg (C26H12), FABP4 (D25B3) and GAPDH (D16H11) antibodies (Cell Signaling). Appropriate secondary HRP-conjugated antibodies were used for chemiluminescence detection (Pierce ECL plus, Thermo Scientific). Images were recorded on CCD (Syngene GeneGnome, Frederick, MD, USA) at 30 s intervals. Densitometric analysis of western blot bands was performed using ImageJ software (NIH). Different exposures were used for GAPDH, PPARg, and FABP4 bands.
qRT-PCR. Total RNA was extracted using RNAeasy Extraction Kit (Qiagen). Sample amount was determined by spectrophotometric quantification with Nanodrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). Then, 500 pg RNA was reverse transcribed with QuantiTect Reverse Transcription Kit Statistical analysis. Data analysis was performed using the SPSS/Win program version 18 (Spss, Chicago, IL, USA). Mean values were compared by a two-tailed t-test. The level of statistical significance was defined by a two-tailed P-value. Po0.05 was considered significant.
